Trial Profile
An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2014
Price :
$35
*
At a glance
- Drugs Kanglaite (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors KangLaiTe USA
- 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Jul 2012 New trial record